Portola Pharmaceuticals Inc (PTLA) 34.96 $PTLA
More Good News: Update On Portola As The Stock Pushes Toward All-Time Highs
DoctoRx - at Seeking Alpha - Fri Feb 13, 6:30AM CST
PTLA: 34.96 (+3.13)
Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Directors
GlobeNewswire - Mon Feb 09, 3:00PM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced the appointment of Laura Brege and Dennis Fenton, Ph.D., to its board of directors. Ms. Brege serves as president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Dr. Fenton is the owner and chief executive officer of Fenton and Associates, a biotechnology consulting firm.
PTLA: 34.96 (+3.13)
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 06, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
PXLW: 5.24 (-0.22), PCOM: 11.68 (-0.18), PTLA: 34.96 (+3.13), UBNT: 28.78 (-1.88), VBLT: 14.11 (+0.24), CBMG: 24.32 (-1.17)
Why Shares of Portola Pharmaceuticals, Inc. Soared
George Budwell, The Motley Fool - Motley Fool - Fri Feb 06, 11:18AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the developmental-stage biopharma Portola...
PTLA: 34.96 (+3.13)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 4:35PM CST
MXWL: 6.47 (+0.07), GSB: 3.15 (+0.11), UBNT: 28.78 (-1.88), PTLA: 34.96 (+3.13), P: 15.44 (+0.45), FWM: 5.55 (+0.08), NTGR: 31.63 (+0.23), TWTR: 48.50 (+0.55), YRCW: 19.65 (+0.21), CTRL: 13.39 (+0.10)
Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Planned and Remains on Track for Enrollment Completion by Year-End
GlobeNewswire - Thu Feb 05, 3:10PM CST
Portola Pharmaceuticals (Nasdaq TLA) today announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned without modification based on the successful completion of a pre-specified futility analysis. In making this recommendation, the IDMC evaluated preliminary efficacy trends and safety reports from the first half of the study. The APEX Study is assessing betrixaban, an oral, once-daily, investigational Factor Xa inhibitor, for both hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients. Acute medically ill patients are those who are hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease.
PTLA: 34.96 (+3.13)
3 Small-Cap Biotech Stocks That Could Be Top Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 31, 12:06PM CST
Source: Flickr user stockmonkeys.com . The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech...
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Portola Pharmaceuticals Announces Dr. Robert Califf Retires From the Board of Directors to Accept Position as Deputy Commissioner for Medical Products and Tobacco at the Food and Drug Administration (FDA)
GlobeNewswire - Mon Jan 26, 10:53AM CST
Portola Pharmaceuticals (Nasdaq TLA) announced that Robert Califf, M.D., has retired from Portola's Board of Directors. Dr. Califf has accepted a position as the Deputy Commissioner for Medical Products and Tobacco at the FDA, as announced today in a press release issued by the agency. Dr. Califf was first elected to Portola's Board of Directors in 2012.
PTLA: 34.96 (+3.13)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
After Phase 3 Success, Portola Is A Buy
Value Insight - at Seeking Alpha - Thu Jan 15, 7:28AM CST
PTLA: 34.96 (+3.13)
First Week of PTLA February 20th Options Trading
DividendChannel.com - Mon Jan 12, 10:17AM CST
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the February 20th expiration.
PTLA: 34.96 (+3.13)
Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote
GlobeNewswire - Mon Jan 12, 8:16AM CST
Portola Pharmaceuticals (Nasdaq TLA) today announced the initiation of a single-arm Phase 4 study to support the approval of andexanet alfa by the U.S. Food and Drug Administration (FDA) under an Accelerated Approval pathway. Portola is developing this FDA-designated breakthrough therapy as a universal antidote for patients receiving a Factor Xa inhibitor anticoagulant who suffer a major bleeding episode or who may require emergency surgery.
PTLA: 34.96 (+3.13)
Why Johnson & Johnson Is Cheering on This Small Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 6:02AM CST
Source: Johnson & Johnson Johnson & Johnson is one of the globe's biggest drugmakers, so it may be a bit surprising to learn that J&J has a lot riding on the success of Portola Pharmaceuticals , a small cap biotech company that is...
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:10AM CST
SD: 2.09 (+0.14), PTLA: 34.96 (+3.13), EOPN: 8.55 (-0.01), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), INFY: 36.60 (-0.13), FIVE: 33.01 (+0.11), AGEN: 5.03 (-0.01), SAN: 7.18 (+0.13), EDAP: 3.55 (+0.13), GMLP: 28.17 (+0.45), CTSO: 8.20 (+0.18), SBLK: 4.48 (+0.15), IDN: 1.43 (-0.01)
Portola anticoagulant antidote successful in clinical study
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:24AM CST
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13)
Portola Announces Phase 3 ANNEXA-R Study of Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance
GlobeNewswire - Fri Jan 09, 7:07AM CST
Portola Pharmaceuticals (Nasdaq TLA) today announced topline results from the first part of the Phase 3 ANNEXA(TM)-R (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Rivaroxaban) study, which is evaluating the safety and efficacy of andexanet alfa with the Factor Xa inhibitor XARELTO (rivaroxaban). Results showed that the study met its primary endpoint with high statistical significance. Andexanet alfa administered as an intravenous (IV) bolus significantly and immediately reversed the steady-state anticoagulation activity of XARELTO and was well tolerated. The Company expects to present the full data set at the American College of Cardiology's (ACC) 64 Annual Scientific Session in San Diego on Monday, March 16 at 11:30 a.m. PT in an oral session titled "Highlighted Original Research: Acute Coronary Syndromes and the Year in Review." The second part of the ANNEXA-R study, which is evaluating a bolus plus a continuous infusion of andexanet alfa to sustain reversal, is ongoing.
PTLA: 34.96 (+3.13)
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 12, 2015
GlobeNewswire - Tue Jan 06, 3:00PM CST
Portola Pharmaceuticals (Nasdaq TLA) today announced that it will host an investor webcast on Monday, January 12, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time), which will coincide with the 33 Annual J.P. Morgan Healthcare Conference in San Francisco. During the event, Portola's senior management team will provide an update on the Company's recent business progress.
PTLA: 34.96 (+3.13), JPM: 59.67 (+0.10)
More Good News: Update On Portola As The Stock Pushes Toward All-Time Highs
DoctoRx - at Seeking Alpha - Fri Feb 13, 6:30AM CST
PTLA: 34.96 (+3.13)
Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Directors
GlobeNewswire - Mon Feb 09, 3:00PM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced the appointment of Laura Brege and Dennis Fenton, Ph.D., to its board of directors. Ms. Brege serves as president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Dr. Fenton is the owner and chief executive officer of Fenton and Associates, a biotechnology consulting firm. PTLA: 34.96 (+3.13)
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 06, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
PXLW: 5.24 (-0.22), PCOM: 11.68 (-0.18), PTLA: 34.96 (+3.13), UBNT: 28.78 (-1.88), VBLT: 14.11 (+0.24), CBMG: 24.32 (-1.17)
Why Shares of Portola Pharmaceuticals, Inc. Soared
George Budwell, The Motley Fool - Motley Fool - Fri Feb 06, 11:18AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the developmental-stage biopharma Portola...
PTLA: 34.96 (+3.13)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 4:35PM CST
MXWL: 6.47 (+0.07), GSB: 3.15 (+0.11), UBNT: 28.78 (-1.88), PTLA: 34.96 (+3.13), P: 15.44 (+0.45), FWM: 5.55 (+0.08), NTGR: 31.63 (+0.23), TWTR: 48.50 (+0.55), YRCW: 19.65 (+0.21), CTRL: 13.39 (+0.10)
Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Planned and Remains on Track for Enrollment Completion by Year-End
GlobeNewswire - Thu Feb 05, 3:10PM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned without modification based on the successful completion of a pre-specified futility analysis. In making this recommendation, the IDMC evaluated preliminary efficacy trends and safety reports from the first half of the study. The APEX Study is assessing betrixaban, an oral, once-daily, investigational Factor Xa inhibitor, for both hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients. Acute medically ill patients are those who are hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease. PTLA: 34.96 (+3.13)
3 Small-Cap Biotech Stocks That Could Be Top Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 31, 12:06PM CST
Source: Flickr user stockmonkeys.com . The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech...
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Portola Pharmaceuticals Announces Dr. Robert Califf Retires From the Board of Directors to Accept Position as Deputy Commissioner for Medical Products and Tobacco at the Food and Drug Administration (FDA)
GlobeNewswire - Mon Jan 26, 10:53AM CST
Portola Pharmaceuticals (Nasdaq
TLA) announced that Robert Califf, M.D., has retired from Portola's Board of Directors. Dr. Califf has accepted a position as the Deputy Commissioner for Medical Products and Tobacco at the FDA, as announced today in a press release issued by the agency. Dr. Califf was first elected to Portola's Board of Directors in 2012. PTLA: 34.96 (+3.13)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
After Phase 3 Success, Portola Is A Buy
Value Insight - at Seeking Alpha - Thu Jan 15, 7:28AM CST
PTLA: 34.96 (+3.13)
First Week of PTLA February 20th Options Trading
DividendChannel.com - Mon Jan 12, 10:17AM CST
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the February 20th expiration.
PTLA: 34.96 (+3.13)
Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote
GlobeNewswire - Mon Jan 12, 8:16AM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced the initiation of a single-arm Phase 4 study to support the approval of andexanet alfa by the U.S. Food and Drug Administration (FDA) under an Accelerated Approval pathway. Portola is developing this FDA-designated breakthrough therapy as a universal antidote for patients receiving a Factor Xa inhibitor anticoagulant who suffer a major bleeding episode or who may require emergency surgery. PTLA: 34.96 (+3.13)
Why Johnson & Johnson Is Cheering on This Small Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 6:02AM CST
Source: Johnson & Johnson Johnson & Johnson is one of the globe's biggest drugmakers, so it may be a bit surprising to learn that J&J has a lot riding on the success of Portola Pharmaceuticals , a small cap biotech company that is...
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:10AM CST
SD: 2.09 (+0.14), PTLA: 34.96 (+3.13), EOPN: 8.55 (-0.01), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), INFY: 36.60 (-0.13), FIVE: 33.01 (+0.11), AGEN: 5.03 (-0.01), SAN: 7.18 (+0.13), EDAP: 3.55 (+0.13), GMLP: 28.17 (+0.45), CTSO: 8.20 (+0.18), SBLK: 4.48 (+0.15), IDN: 1.43 (-0.01)
Portola anticoagulant antidote successful in clinical study
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:24AM CST
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13)
Portola Announces Phase 3 ANNEXA-R Study of Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance
GlobeNewswire - Fri Jan 09, 7:07AM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced topline results from the first part of the Phase 3 ANNEXA(TM)-R (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Rivaroxaban) study, which is evaluating the safety and efficacy of andexanet alfa with the Factor Xa inhibitor XARELTO (rivaroxaban). Results showed that the study met its primary endpoint with high statistical significance. Andexanet alfa administered as an intravenous (IV) bolus significantly and immediately reversed the steady-state anticoagulation activity of XARELTO and was well tolerated. The Company expects to present the full data set at the American College of Cardiology's (ACC) 64 Annual Scientific Session in San Diego on Monday, March 16 at 11:30 a.m. PT in an oral session titled "Highlighted Original Research: Acute Coronary Syndromes and the Year in Review." The second part of the ANNEXA-R study, which is evaluating a bolus plus a continuous infusion of andexanet alfa to sustain reversal, is ongoing. PTLA: 34.96 (+3.13)
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 12, 2015
GlobeNewswire - Tue Jan 06, 3:00PM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it will host an investor webcast on Monday, January 12, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time), which will coincide with the 33 Annual J.P. Morgan Healthcare Conference in San Francisco. During the event, Portola's senior management team will provide an update on the Company's recent business progress. PTLA: 34.96 (+3.13), JPM: 59.67 (+0.10)
